OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. (Record no. 26201393)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02151 a2200577 4500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250517104010.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 201705s 0 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1097-0215 |
| 024 7# - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1002/ijc.30256 |
| Source of number or code | doi |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | NLM |
| Language of cataloging | eng |
| Transcribing agency | NLM |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Berenguer-Daizé, Caroline |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 20170501 |
| 245 00 - TITLE STATEMENT | |
| Title | OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models. |
| Medium | [electronic resource] |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Name of publisher, distributor, etc. | International journal of cancer |
| Date of publication, distribution, etc. | 11 2016 |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 2047-55 p. |
| Other physical details | digital |
| 500 ## - GENERAL NOTE | |
| General note | Publication Type: Journal Article |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Acetanilides |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Animals |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Agents |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic Combined Chemotherapy Protocols |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Blood-Brain Barrier |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Brain Neoplasms |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Camptothecin |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cell Line, Tumor |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cell Proliferation |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cell Survival |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Dacarbazine |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Drug Synergism |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Everolimus |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Gene Expression Regulation, Neoplastic |
| General subdivision | drug effects |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Glioblastoma |
| General subdivision | drug therapy |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Heterocyclic Compounds, 3-Ring |
| General subdivision | administration & dosage |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Humans |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Irinotecan |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Mice |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Temozolomide |
| 650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Xenograft Model Antitumor Assays |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Astorgues-Xerri, Lucile |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Odore, Elodie |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cayol, Mylène |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Cvitkovic, Esteban |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Noel, Kay |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Bekradda, Mohamed |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | MacKenzie, Sarah |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Rezai, Keyvan |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Lokiec, François |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Riveiro, Maria E |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ouafik, L'Houcine |
| 773 0# - HOST ITEM ENTRY | |
| Title | International journal of cancer |
| Related parts | vol. 139 |
| -- | no. 9 |
| -- | p. 2047-55 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://doi.org/10.1002/ijc.30256">https://doi.org/10.1002/ijc.30256</a> |
| Public note | Available from publisher's website |
No items available.